Brief: Abbisko Cayman Says Unit Entered A Worldwide Collaboration And Exclusive Licensing Deal With Eli Lilly
18/01/2022 01:03
Jan 18 (Reuters) - Abbisko Cayman Ltd 2256.HK :
* UNIT ENTERED INTO A WORLDWIDE COLLABORATION AND EXCLUSIVE
LICENSING AGREEMENT WITH ELI LILLY AND CO
* DEAL FOR FURTHER DEVELOPMENT & POTENTIAL COMMERCIALIZATION
OF
NOVEL MOLECULES AGAINST UNDISCLOSED TARGET FOR CARDIOMETABOLIC
DISEASES
Further company coverage: 2256.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Cayman
See all newsHK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)
Brief: Abbisko Therapeutics Deepens R+D- Collaboration With Lilly
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly